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Gliomas are the most common brain tumors, with diverse biological behaviour. Glioblastoma (GBM), 
the most aggressive and with the worst prognosis, is characterized by an intense and aberrant 
angiogenesis, which distinguishes it from low-grade gliomas (LGGs) and benign expansive lesions, as 
meningiomas (MNGs). With increasing evidence for the importance of vascularization in tumor biology, 
we focused on the isolation and characterization of endothelial cells (ECs) from primary GBMs, LGGs and 
MNGs. Gene expression analysis by Real-Time PCR, immunofluorescence and flow cytometry analysis, 
tube-like structures formation and vascular permeability assays were performed. Our results showed 
a higher efficiency of ECs to form a complex vascular architecture, as well as a greater impairment of a 
brain blood barrier model, and an overexpression of pro-angiogenic mediators in GBM than in LGG and 
MNG. Furthermore, administration of temozolomide, bevacizumab, and sunitinib triggered a different 
proliferative, apoptotic and angiogenic response, in a dose and time-dependent manner. An increased 
resistance to temozolomide was observed in T98G cells co-cultured in GBM-EC conditioned media. 
Therefore, we developed a novel platform to reproduce tumor vascularization as “disease in a dish”, 
which allows us to perform screening of sensitivity/resistance to drugs, in order to optimize targeted 
approaches to GBM therapy.
Central Nervous System (CNS) tumors are among the most complex human cancers, with a prognosis closely 
related to histological classification, location, genetic background and specific microenvironment of the tumor. 
Brain tumors present anatomically similar features, but they differ significantly for morphology, aetiology, site 
of origin, molecular biology and clinical progression1. In adults, about 50% of all CNS tumors are malignant, 
whereas in paediatric patients, more than 75%2. The ability of tumor mass to grow, progress and infiltrate into 
surrounding tissue, compromising cognitive and motor skills, is due to the intense and aberrant angiogenesis, 
responsible for the formation of new blood vessels, which support tumor development, providing nutrition, oxy-
gen and energy3, in a mechanism well known as neovascularization. Angiogenesis is regulated by a number of 
both stimulating and inhibiting angiogenic factors acting on endothelial cells (ECs)4. Often, concentration of 
pro-angiogenic mediators increase progressively with tumor grade and is linked with the clinical outcome5. In 
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this complex process of neovascularization, tumor ECs are the protagonists, and their cellular and molecular 
properties, specific of tumor grade, affect their functionality and, consequently, tumor response to therapies. 
Microvascular proliferation, indeed, is a key feature of glioma grading: it is quite absent in low grade gliomas 
(LGGs, WHO II) and observed in malignant high-grade gliomas, HGGs (WHO, grades III, and IV), the tumor 
with the worst prognosis. On the contrary, although meningiomas (MNGs, WHO grade I) represent tumors 
with a very high degree of vascularization, they show non-aggressive biology, resulting in the most favoura-
ble long-term survival (median, 12–15 years)6. The most common and malignant human intracranial cancer is 
glioblastoma (GBM), classified as WHO grade IV, with a complex biology characterized by uncontrolled pro-
liferation, diffuse infiltration, hypervascularization and resistance to therapies. Standard first line management 
for newly diagnosed GBM involves a multi-modality approach, including surgical resection, followed by radia-
tion with concurrent and adjuvant Temozolomide (TMZ). Despite countless experimental researches for new 
therapeutic strategies and promising clinical trials, the prognosis remains extremely poor, with a mean survival 
of less than 14 months7,8. Bevacizumab (BEV), a humanized monoclonal antibody against vascular endothelial 
growth factor (VEGF), has increasingly been used in the treatment of recurrent GBM, due to promising trial 
results demonstrating improved response rates. Unfortunately, BEV effects are only transient and GBM recur-
rence is not avoided9. Interestingly, sunitinib (SUN), a multitargeted antiangiogenic tyrosine kinase inhibitor 
(TKI) has attracted the attention of the scientific community for its ability to inhibit angiogenesis in different 
tumors10,11, proving to be a potential candidate to counteract neovascularization in GBM. The ability of micro-
vascular ECs to respond dynamically to pathology-related microenvironment changes is particularly apparent in 
tumor-growth-associated angiogenesis. The heterogeneity of brain tumors, as well as the need to improve patient 
response to therapies, in terms of progression-free survival and quality of life, brings to mind the idea of develop-
ing patient-specific personalized therapies, based on cellular response to treatments. In this regard, the possibility 
to develop a primary EC characterization platform, biologically as close as possible to the in situ situation, as 
“disease in a dish”, greatly valorises brain tumor angiogenesis investigation, improving pharmacologic screening 
and, in turn, target therapies.
Results
Phenotypic analysis revealed a higher pro-angiogenic expression pattern in GBM than in LGG 
and MNG. Immunoistochemical labelling proved the higher CD34 expression pattern in GBM sections com-
pared to those of LGG and MNG. Quantification of integrated density reported an average value for field of 
25,7 ± 3,65 (AU) for GMBs, 7,82 ± 1,03 for LGGs and 3,96 ± 1,26 for MNGs (Fig. 1A). Primary ECs isolated 
from GBMs, LGGs and MNGs were cultured and expanded in Endothelial Proliferation medium (EndoPM), 
growing as a typical cobblestone monolayer (Fig. 1A). Immunofluorescence analysis revealed positivity for the 
endothelial markers von Willebrand factor (VWF), vascular endothelial growth factor receptror-1 (VEGFR-1) 
and VE-Cadherin, thus confirming their endothelial phenotype (Fig. 1A). In particular, GBM-ECs were able to 
form VWF fibers, confirming the higher activation level of ECs derived from GBMs, compared to those derived 
from LGGs and MNGs. As notable, fluorescence intensity is considerably greater in GBM-ECs compared to LGG-
ECs and MNG-ECs, not only regarding VWF but also VEGFR-1, suggesting an overexpression of endothelial 
functional markers, essential for angiogenesis promotion. On the contrary, a lower intensity in GBM-ECs com-
pared to LGG-ECs and MNGs was observed for VE-Cadherin labelling. Notably, no positive labelling for GFAP, 
SMA and CD68 was observed (Supplementary Table 1).
GBM-ECs grow with an exponential rate, unlike LGG- and MNG-ECs. In order to estimate the pro-
liferation rate of ECs, a growth curve of 14 days was performed. In the first steps of cell cultures, GBM-, LGG- and 
MNG-ECs showed the same proliferation rate. Up to 96 h after seeding in fact, ECs grew with the same trend, 
reaching a cell number of about 5-fold higher than at start time. However, from 48 h to 14 days, GBM-ECs grew 
with an exponential proliferation rate, being in number 2- and 3-fold higher than LGG-ECs and MNG-ECs, 
respectively. On the contrary, LGG-ECs and MNG-ECs showed a rather exponential proliferation rate from 48 h 
to 7 days, after which they slowed growth, reaching a plateau stage (Fig. 1B).
FACS analysis showed a different expression profile in brain tumor ECs. FACS analysis revealed 
interesting different and specific expression pattern, closely related to tumor malignancy and neovascularization. 
CD105 was overexpressed in GBM-ECs compared to LGG-ECs and MNG-ECs (Fig. 1C). In the ECs popula-
tions analysed, about 90 ± 5% of GBM-ECs were positive for CD105, whereas 60 ± 7% and 5 ± 4% of LGG-ECs 
and MNG-ECs were positive, respectively. GBM-ECs positivity of 55 ± 12% for CD133, compared to LGGs and 
MNGs where CD133-positive ECs were only about 6 ± 4% and 3 ± 2% respectively. CD56 and CD90 showed the 
same trend. About 75 ± 9%, 6 ± 5% and 4 ± 3% of ECs derived from GBMs, LGGs and MNGs were positive to 
CD56, whereas 96 ± 9%, 68 ± 8% and 26 ± 5% were positive to CD90, respectively (Fig. 1D).
GBM-ECs, LGG-ECs and MNG -ECs showed a different ability to form tube-like structures. The 
analysis of tube-like structures formation assay (Fig. 2A), revealed that GBM-ECs were able to form a complex 
and branched architecture. After 24 h, GBM-ECs were able to form junctions, cords and meshes, showing the 
ability to create an intense vasculature. On the contrary, LGG-ECs and MNG-ECs failed to form tube-like struc-
tures, lacking of an organized network. In particular, GBM-ECs succeeded to form a number of segment 2- and 
4-fold higher than LGG- and MNG-ECs respectively, as well a number of meshes about 3- and 6- fold higher. 
Regarding total tube length, we observed an increase of about 1.5- and 3-fold in GBM-ECs compared to LGG- 
and MNG-ECs.
GBM-ECs present an increased vascular permeability compared to LGG-ECs and MNG-ECs. 
Vascular permeability assay was performed in order to evaluate the different permeability rate of ECs derived 
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from different brain tumors and investigate the functionality of BBB. The histogram in Fig. 2B shows the amount 
of FITC-70 kDa dextran that succeeded to cross the cellular barrier formed by GBM-EC, LGG-EC and MNG-EC 
monolayer. As shown, there was a notable time-dependent trend, so the concentration of dextran detectable in the 
lower chamber increased over time. Notably, the amount of FITC-70 kDa dextran that passed across GBM-ECs 
barrier was significantly higher compared to LGG-ECs and MNG-ECs samples, indicating that GBM-ECs form 
a weak and defenestrated barrier.
Brain tumor derived ECs showed significant differences in mRNA expression of angiogenic 
mediators. In order to investigate the complex microenvironment of brain tumors, qRT-PCR was performed 
on the entire tumor sample homogenates of GBMs, LGGs and MNGs (Fig. 3). Results were compared to those 
obtained from healthy brain (HB), used as control. Our data reported that vascular endothelial growth factor 
(VEGF) mRNA was up 70-, 15- and 7-fold overexpressed in GBM, LGG and MNG, respectively, compared 
with HB. Similar results were observed in mRNA expression of both VEGFR-1 and angiopoietin-2 (Ang-2), 
whose levels were about 80-, 20- and 8-fold higher in GBM, LGG, and MNG, respectively, compared with HB. 
Notably, VWF, hypoxia inducible factor 1 (HIF-1), neural cell adhesion molecule (NCAM), fibroblastic growth 
factor-2 (FGF-2), and angiopoietin receptor Tie-2 mRNA levels followed a similar trend, showing a significant 
up-regulation in GBM, compared to LGG, MNG, and HB. On the contrary, mRNA expression of Ang-1 was sig-
nificantly lower in GBM and LGG, whereas was quite similar in MNG.
Drug treatment effects on GBM-ECs viability. In order to test drug effect on GBM-EC viability, MTT 
assay was performed 24 h and 48 h after treatment. Data revealed that BEV and TMZ were able to decrease cells 
viability after 24 h at 87% and 81% for BEV 100 and 200 µg/mL and 82% and 77% for TMZ, 100 and 200 µM, 
respectively. Notably, at 48 h their effect disappeared, suggesting that the initial positive effect of pharmacological 
Figure 1. Isolation, expansion and characterization of primary GBM, LGG and MNG-derived ECs. (A) 
Immunohistochemical staining for CD34 in GBM, LGG and MNG sections revealed an higher expression 
in GBM than in LGG and MNG. After tumor sample processing, GBM-ECs, LGG-ECs and MNG-ECs were 
isolated and expanded. As shown, ECs were able to form a “cobblestone” monolayer (inverted phase-contrast 
microscopy). Immunofluorescence labelling for VWF (green fluorescent labelling), VEGFR-1(red fluorescent 
labelling) and VE-Cadherin(red fluorescent labelling) was performed on cultured ECs. The white box contains 
an enlargement of the image. Scale bar 50 µm. (B) Estimation of proliferation rate of GBM-ECs, LGG-ECs, 
MNG-ECs for 14 days after seeding. (C) Representative cytofluorimetric dot plots of GBM-ECs, LGG-ECs and 
MNG-ECs stained with FITC-conjugated anti-human CD105 and PE-conjugated anti-human CD133, anti-
human CD56, anti-human CD90. Analysis were performed after doublets and dead cells exclusion.  
(D) Quantification of the positive cell population in percentage. Data are the means of ±SD of three independent 
experiments. *GMB vs MNG, #GBM vs LGG, ◊LGG vs MNG. *#◊P < 0.05, **P < 0.01, ***, ###, ◊◊◊P < 0.001
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inhibition did not last over time. Indeed, following 48 h of treatment the viability was quite similar to untreated 
control. On the contrary, SUN at 5 µM had almost no effect at 24 h, when viable cells were about 95%, whereas at 
10 µM viability decreased at about 80%. Interestingly, after 48 h, SUN effect was enhanced, and viability was about 
82% and 66% at 5 µM and 10 µM, respectively (Fig. 4A).
Tube-formation ability of GBM-ECs is differently affected by drugs administration. BEV, TMZ 
and SUN proved the ability to inhibit significantly tube-like structures formation after 24 h of treatment. Indeed, 
as shown in Fig. 4B,C, at 24 h, number of segments and meshes was approximately halved after treatment with 
BEV 200 µg/ml and TMZ 200 µM and also total tube length was significantly decreased. It is noteworthy that these 
data were not confirmed at 48 h. Indeed, after prolonged treatment, ECs seem to recover their ability to form 
tube-like structures, mitigating or even abolishing BEV and TMZ inhibition. Interestingly, GBM-ECs treated 
with SUN showed a different behaviour. The effect of SUN, in fact, at 24 h was lower compared to that of BEV and 
TMZ, but it was constant over time, both in terms of number of segments, meshes and total tube length.
Gene expression performed with qRT-PCR suggest a different response of GBM-ECs to drugs. 
qRT-PCR revealed an interesting mRNA expression profile in response to 48 h of pharmacologic treatment 
(Fig. 5). Tumor suppressor p53 mRNA expression suffered a significant decrease after treatment with BEV and 
TMZ, in a dose-dependent manner. In particular, BEV showed a more effective action, especially at the higher 
concentration, causing a downregulation of 3-and 7-fold at 100 µg/ml and 200 µg/ml, respectively, compared to 
control (CTRL). A similar but less marked trend was observed after treatment with TMZ. On the contrary, p53 
was up-regulated after SUN administration both at 5 and 10 µM. RAS, ERK-1, PI3K and AKT mRNA expres-
sion was not affected by BEV and TMZ, at the two administered concentrations, whereas interestingly, SUN 
significantly decreased their levels of about 5-fold. Regarding apoptosis regulators, BCL-2 and BAX mRNA 
expression underwent a significant increase after drug treatment with BEV, TMZ and SUN. Interestingly the ratio 
BCL-2/BAX mRNA expression was in favour of the anti-apoptotic BCL-2 for BEV and TMZ, and in favour of the 
pro-apoptotic BAX for SUN. Moreover, qRT-PCR was performed to evaluate the effect of drug administration on 
gene expression of angiogenic factors (Fig. 6). Results showed a significant overexpression of VEGF, VEGFR-1 
Figure 2. Tube-like structure formation and vascular permeability assays. (A) Representative images of 
tube-like structures formation assay performed on GBM-ECs, LGG-ECs and MNG-ECs seeded on Matrigel. 
Numbers of segment, meshes and total tube length were measured using Angiogenesis Analyzer plugin in 
ImageJ. Data are the mean ± SD of at least three experiments in triplicate. Scale bar, 500 µm. (B) Vascular 
permeability assay performed administrating FITC-70 kDa on GBM-ECs, LGG-ECs and MNG-ECs confluent 
monolayer cultured in Transwell insert. Data are the mean ± SD of three experiments in triplicate. *GBM vs 
MNG, #GBM vs LGG, ◊LGG vs MNG. *P < 0.05, **, ◊◊P < 0.01, ***, ###, ◊◊◊P < 0.001.
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and VEGFR-2 after treatment with BEV. An opposite effect was observed after treatment with SUN, which caused 
a drastic downregulation at both concentration. Regarding Ang-2 and VWF, a similar but less strong trend was 
observed. On the contrary, Tie-2 mRNA expression was decreased after drug treatment with BEV and SUN. All 
gene expression alteration followed a dose-dependent trend. Interestingly, administration of TMZ did not affect 
mRNA expression levels of each investigated marker.
T98G cells viability after TMZ administration is affected by ECs conditioned media. To evalu-
ate if ECs from GBM, LGG and MNG may influence drug efficacy, co-colture experiments were performed. In 
particular, T98G cells were cultured with GBM-EC, LGG-EC and MNG-EC conditioned media (-CM). In this 
regard, MTT assay revealed that TMZ 200 µM, after 48 h, decreased cell viability of about 40%, suggesting a sensi-
tive response to chemotherapy(Fig. 7A). Noteworthy, combined treatment of T98G cells with TMZ + GBM-CM, 
significantly increased cell viability of about 25% compared to TMZ alone. Notably, this effect was not observed 
following combined treatment with TMZ + LGG-CM and TMZ + MNG-CM.
GBM-CM induces resistance to TMZ in T98G cells. qRT-PCR was performed to detect changes in 
mRNA expression of proliferation and apoptotic regulators on T98G cells, treated with TMZ alone or in combina-
tion with GBM-, LGG- and MNG-CM (Fig. 7B). Our results showed that T98G were sensitive to TMZ treatment, 
but its effect was suppressed when GBM-CM was added to the culture. In detail, mRNA expression of tumor 
suppressor p53 increased of about 3-fold after TMZ treatment, and its expression decreased significantly when 
T98G were treated with TMZ + GBM-CM. A similar but not so strong effect, was observed when T98G cells 
were treated with TMZ + LGG-CM and TMZ + MNG-CM. mRNA expression of cell survival and proliferation 
markers as RAS, AKT and PI3K was decreased of about 50% after TMZ administration and, also in this case, the 
effect of TMZ was inhibited by GBM-CM. Regarding apoptosis regulators BCL-2 and BAX, despite TMZ was able 
to decrease mRNA expression of the anti-apoptotic BCL-2 and to increase mRNA expression of the pro-apoptotic 
BAX, GBM-CM had the great effect to antagonize its action, inducing the opposite outcome.
Discussion
Malignant gliomas are highly infiltrative tumors and this characteristic is the main factor for the inevitable tumor 
recurrence and short survival after aggressive therapies. The “angiogenic switch” responsible for the formation of 
new blood vessels, leads to an overproduction of pro-angiogenic factors, resulting in uncontrolled proliferation, 
Figure 3. Gene expression profile of GBM, LGG and MNG tumor tissues. qRT-PCR performed on tumor 
samples homogenates. Data were calculated using the 2−ΔΔCt method, normalized to 18S expression, 
and results are presented as a fold change relative to healthy brain (HB). Primer sequences are listed in the 
Supplementary Table 2. Data are the mean of ±SD of three independent experiments. *GBM, LGG, MNG vs 
HB *P < 0.05, **P < 0.01.
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infiltration and progression of tumor mass12. Heterogeneous vascular compartment has been described in various 
tumor types at different tumor stages, and even within a single tumor stage13. In addition to differences in vascular 
morphology, the endothelial fenestration pattern and gene expression profile of the respective vasculatures are 
often variable and affect differently therapeutic efficacy of antiangiogenic drugs with various molecular targets14. 
Our study was focused on the comparison of angiogenic properties of different grades of brain tumors, in order 
to evaluate ECs functionality, pro-angiogenic factor expression, and their contribution on drug resistance/sensi-
tivity of GBM tumor cells. Starting with the phenotypic characterization, GBM showed a higher intensity label-
ling for CD34 than LGG and MNG ones. CD34 expression has been demonstrated to play a crucial role in the 
regulation of glioma angiogenesis by promoting a new blood vessel network and driving further glioma growth. 
According with our results, Rahmah et al. founded that HGGs showed higher expression of CD34 compared to 
LGG, maybe correlated with an higher densities of blood vessels15. Our results demonstrated a significant 
increased positivity for endothelial marker in GBM-ECs compared to LGG-ECs and MNG-ECs15. VWF fibers are 
a peculiar feature of highly activated ECs and microvascular proliferation16. ECs-released VWF fibers markedly 
bind platelets, forming aggregates that may protect cancer cells from immune cells, or may directly influence 
tumor extravasation of activating-ECs factors. Several reports have described a direct interaction between the 
staining intensity of VWF in ECs and the different grade of brain tumors17. Our previous studies showed that 
GBM patients had supraphysiological plasma VWF antigen level that correlates with poor prognosis and shorter 
survival18. Here, the overexpression of VWF was confirmed also by mRNA expression in GBM, compared not 
only to normal brain, but also to LGG and MNG, confirming its correlation with tumor malignancy and its poten-
tial use as prognostic factor. Upon ECs activation, VWF is released from ECs with other proangiogenic factors, as 
VEGF and Ang-2. VEGF is certainly the best characterized pro-angiogenic mediator and its overexpression leads 
to the formation of fragile microvessels, with a disrupted structure and increased permeability19,20. VEGF exerts 
its many effects promoting ECs proliferation, migration and survival and several studies reported a strictly corre-
lation between VEGF, microvascular density and tumor grade and, consequently, with clinical outcome and prog-
nosis21,22. Together with these findings, our results showed that mRNA expression of VEGF, and its receptor 
VEGFR-1, was significantly increased in GBM, compared to both healthy brain, LGG, and MNG. These data 
suggest that angiogenesis is a key mechanism of GBM progression, but is not equally enhanced in LGG and 
MNG, confirming the importance of the signalling pathway VEGF/VEGFR in tumor angiogenesis. Moreover, the 
overexpression of HIF-1α is strictly related to glioma malignancy and several studies reported its association with 
poor prognosis in different types of cancer, including gliomas23. Also, angiopoietins (Ang) and their receptor, 
Figure 4. Tube-like structures formation and cell viability on GBM-ECs after drugs administration. (A) MTT 
assay on GBM-ECs treated with BEV 100 µg/mL and 200 µg/mL, TMZ 100 µM and 200 µM, SUN 5 µM and 
10 µM after 24 h and 48 h. Data are presented as a percentage of viable cell relative to untreated control (CTRL). 
(B) Representative images of tube-like structures formation assay performed on GBM-ECs cultured in basal 
condition or in combination with BEV 200 µg/ml, TMZ 200 µM and SUN 10 µM for 24 h and 48 h. (C) Numbers 
of segment, meshes and total tube length were measured using Angiogenesis Analyzer plugin in ImageJ. Data 
are the mean ± SD of at least three experiments in triplicate. Scale bar, 500 µm. *BEV, TMZ, SUN vs CTRL. 
*P < 0.05, **P < 0.01, ***P < 0.001.
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Tie-2, play a critical role in angiogenesis and vascular stability24. Ang-1, an agonist for the Tie-2 receptor, pro-
motes interaction between eECs and peri-EC support cells to stabilize vessels, favouring structural integrity and 
maturation of blood vessels25. On the contrary, Ang-2 is an antagonist for the Tie-2 receptor that inhibits compet-
itively binding of Ang-1, triggering endothelium activation and vascular destabilization25. Indeed, Ang-2 acts as 
a proangiogenic agent, promoting establishment of disorganized and defenestrated blood vessels with increased 
permeability and loss of integrity. Interestingly, in our tumor samples, Ang-2 was overexpressed in GBM com-
pared to HB, LGG and MNG and, on the contrary, Ang-1 was significantly downregulated in GBM respect to HB, 
LGG and MNG, highlighting a marked vascular instability in GBM. These results were further confirmed by our 
blood brain barrier (BBB) model, in which GBM-ECs were not able to form a closed and functional barrier, 
allowing the passage of a great quantity of dextran in a time-dependent manner. This increased permeability may 
reflect the impairment of BBB. The leakage of BBB allows plasma proteins extravasation in extravascular space, 
leading to alteration of extracellular matrix and promotion of angiogenesis and it is an important parameter for 
drug therapy, because it might indicate lower drug availability in the tumor region26. The increased permeability 
of GBM-ECs monolayer could be due to the lack of functional adherent and tight junction. This hypothesis may 
be supported by the lower fluorescence intensity of VE-Cadherin labelling in GBM-ECs compared to LGG-ECs 
and MNG-ECs. The VE-Cadherin is a tight junction protein that plays an important role in the integrity of the 
BBB. Therefore, the reduced expression of junctional protein may contribute to leakiness in tumor blood vessels. 
The loss of VE-Cadherin expression in gliomas was recently confirmed by other investigators. In fact, it has been 
demonstrated that in GBMs, tumor microvessels lose the expression of several tight junction proteins27, as 
VE-Cadherin28. A further strengthening of our results arise from tube-like structures formation. GBM-ECs were 
able to form a complex network, characterized by cords, junctions and meshes, better organized and in a greater 
number respect to LGG-ECs and MNG-ECs, which, in the same time frame, did not succeed to form an in vitro 
vascular architecture. These results demonstrate, once again, that abnormal vascular formation is a process 
strongly promoted in GBM respect to LGG and MNG, and this probably correlates with the prognosis. Moreover, 
phenotypic analyses revealed that GBM-ECs were highly positive to CD105, endoglin, a transmembrane glyco-
protein expressed on activated vascular ECs, which acts as accessory protein of the transforming growth factor 
receptor29. In several cancers, endoglin is found on peritumoral and intratumoral vessels and its overexpression 
was observed primarily in malignant lesions, correlating positively with patient outcome and survival rates29. 
Figure 5. Gene expression profile of proliferative and apoptotic markers on GBM-ECs after drug 
administration. qRT-PCR was performed on GBM-ECs cultured in basal condition (CTRL) or in combination 
with BEV 100 µg/mL and 200 µg/mL, TMZ 100 µM and 200 µM, SUN 5 µM and 10 µM for 48 h. Data were 
calculated using the 2−ΔΔCt method, normalized to 18S expression, and results are presented as a fold 
change relative to untreated control (CTRL). Primer sequences are listed in the Supplementary Table 2. Data 
are the mean of ±SD of three independent experiments. *BEV, TMZ, SUN vs CTRL. *P < 0.05, **P < 0.01, 
***P < 0.001.
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Another marker that we found significantly positive in GBM compared to LGG and MNG, was CD90, a highly 
glycosylated protein belonging to the immunoglobulin superfamily, widely characterized in various types of cells 
in normal tissues, including neurons and fibroblasts. Recently, CD90 has become an attractive molecule for can-
cer research because it is now recognized as marker for cancer stem cells in malignant tumors as hepatocellular 
carcinomas30 and GBM31. On the other hand, CD90 is expressed on activated ECs, working as marker for tumor-
igenesis and angiogenesis32. Anyway, the high percentage of LGG-ECs positive to CD105 and CD90 may reflect 
the propensity of LGGs to undergo malignant transformation, developing in secondary GBMs. Another major 
aspect of GBM biology that contributes to its poor prognosis is the presence of a stem cell component with 
self-renewing capacity and differentiation ability, responsible for recurrence events. Moreover, a high percentage 
of GBM-ECs (about 70%), showed positivity to CD56, or NCAM, a cell-surface glycoprotein widely characterized 
in CNS, when it regulates intercellular adhesion and cell migration. Previous studies evidenced a positive associ-
ation between NCAM expression and tumor grade, and in particular between NCAM and cancer aggressive-
ness33. This hypothesis agrees with our evidence that NCAM expression was significantly up-regulated in GBM, 
but not in LGG and MNG.
As mentioned above, our isolation and characterization platform of endothelial compartment of brain tumor 
was developed to test different drug efficacy. To this aim, in this study, we started evaluating the relationship 
between in vitro drug response of primary brain tumor ECs and their expression of selected biomarkers puta-
tively associated with drug resistance. The cellular basis of drug resistance in malignant gliomas and other tumors 
seems to be associated with various mechanisms, including those that prevent drugs from reaching their target 
in active form, enhanced DNA repair, or disruption of the apoptotic response to DNA damage34. After surgical 
resection, the standard of care for patients with newly diagnosed GBM is concurrent radiotherapy and TMZ. 
TMZ is a DNA alkylating agent known to induce cell cycle arrest at G2/M and to eventually lead to apoptosis, 
used to treat GBM and astrocytomas35 The development of resistance towards cytostatic drugs like the first line 
drug TMZ is a problem for GBM treatment, and relapses of the disease are really common36. In the last few years, 
the anti-angiogenesis drug Avastin® (Bevacizumab, BEV), which targets VEGF, has become one of the most 
promising cancer drug, also in GBM9. Anti-angiogenic therapy may lead to vascular normalization and facilitate 
conventional cytotoxic chemotherapy. For these premises, we decided to test the action of TMZ and BEV on our 
primary isolated GBM-ECs. Our data suggested that the effects of BEV and TMZ were transient and the mecha-
nisms of their failure were complex and multifactorial. In this regard, treatments of GBM-ECs with two different 
concentrations, at two time-points, revealed a time- and dose-dependent response. Indeed, both viability and 
tube-like structures formation suggested an inhibitory drug effect at 24 h, which was not confirmed at 48 h, when 
GBM-ECs recovered their endothelial functionality. Surprisingly, treatment with a novel tirosin kinases inhibi-
tor, Sunitinib (SUN) reported a different response pattern, although also time- and dose-dependent. In fact, the 
effect of SUN on viability and tube formation increased overtime, without any significant functional recovery 
following prolonged treatment. Indeed, gene expression analysis of GBM-ECs after pharmacological treatment, 
revealed that tumor suppressor p53 was down-regulation by BEV and TMZ, and up-regulated by SUN. p53, the 
Figure 6. Gene expression profile of angiogenic markers on GBM-ECs after BEV, TMZ and SUN 
administration. qRT-PCR was performed on GBM-ECs cultured in basal condition (CTRL) or in combination 
with BEV 100 µg/mL and 200 µg/mL, TMZ 100 µM and 200 µM, SUN 5 µM and 10 µM for 48 h. Data were 
calculated using the 2−ΔΔCt method, normalized to 18S expression, and results are presented as a fold 
change relative to untreated control (CTRL). Primer sequences are listed in the Supplementary Table 2. Data 
are the mean of ±SD of three independent experiments. *BEV, TMZ, SUN vs CTRL. *P < 0.05, **P < 0.01, 
***P < 0.001.
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“guardian of the genome,” is certainly one of the most widely studied protein in human glioma. Activation of p53 
triggers different cellular programs such as cell cycle arrest, apoptosis, differentiation, DNA repair, autophagy, and 
senescence through complex network and signalling pathways37. The activation of p53 in the cells leads to either 
DNA repair and recovery or apoptosis38 and p53 has also been shown to have an effect on apoptosis by regulating 
BCL-2 and BAX expression. It has been suggested that the ratio of BCL-2 to BAX may determine cell fate, survival 
or death, when exposed to apoptotic stimuli such as pharmacological treatment39. In line with these evidence, 
our results showed that the ratio BCL-2/BAX was in favour of BCL-2 following BEV and TMZ administration. 
Interestingly, SUN switched the ratio in favour of BAX, suggesting its pro-apoptotic effect in our GBM-ECs. 
Overall, our data suggest a resistance response pattern of GBM-ECs towards BEV and TMZ and, on the contrary, 
a sensitivity pattern towards SUN. On the other hand, gene expression of angiogenesis modulators revealed an 
opposite action of BEV versus SUN. Indeed, VEGF, VEGFR1-2 and Ang-2 were upregulated after BEV treatment, 
but significantly downregulated following SUN administration. This effect may be attributed to a compensatory 
self-regulating mechanism that govern aberrant new vessel formation and their relative instability40. One possible 
explanation is that GBM-ECs activate collateral and different signalling pathways in order to overcome angiogen-
esis inhibition caused by BEV. It seems that other vascular factors compensate for the function of VEGF and that 
therefore the angiogenesis cannot be completely inhibited by BEV, weakening its therapeutic efficiency41,42. On 
the contrary, acting as a multi-tyrosine kinase inhibitor, we demonstrated that SUN acted as an anti-angiogenic 
multi-target treatment, affecting more effectively ECs functionality and pro-angiogenic marker expression, sug-
gesting its positive effect on tumor angiogenesis. The effect of SUN could be explained by targeting of different 
VEGF-unrelated receptor tyrosine kinases and other non-endothelial receptors such as CD117 and the receptors 
for Platelet Derived Growth Factor (PDGFR), and for Glial cell line-Derived Neurotrophic Factor (RET)43, as well 
as intracellular targets, showing a multifactorial effect on different signalling pathways regulating tumor cells44,45. 
We further demonstrated that ECs not only showed a resistant behaviour to pharmacological treatments but 
they were able to confer resistance to T98G-sensitive cells. Interestingly, T98G cultured with conditioned media 
from GBM-ECs, LGG-ECs and MNG-ECs changed their response profile, turning into resistant cells. Indeed, 
T98G treated with TMZ in combination with GBM-CM had a percentage of viable cells higher than those treated 
with TMZ alone, as well as higher than those treated with TMZ in combination with LGG-CM and MNG-CM. 
Figure 7. Effect of EC-conditioned media (CM) on T98G response to TMZ administration. (A) MTT assay 
was performed on T98G cultured in basal condition (CTRL), with TMZ 200 µM or in combination of TMZ 
and GBM-EC, LGG-EC and MNG-EC conditioned media (CM), at 24 h and 48 h after treatment. Data are 
presented as a percentage of viable cell relative to untreated control (CTRL). (B) Gene expression profile of 
proliferative and apoptotic markers on T98G in the same conditions listed above. Data were calculated using the 
2−ΔΔCt method, normalized to 18S expression, and results are presented as a fold change relative to untreated 
control (CTRL). #TMZ vs BM, *TMZ + GMB-CM,LGG-CM,MNG-CM vs TMZ. *,#P < 0.05, **,##P < 0.01, 
***P < 0.001.
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mRNA expression level confirmed this trend, reporting the interesting action of GBM-CM in counteracting TMZ 
effect. Notably, the effect produced by LGG-CM and MNG-CM in conferring drug resistance to TMZ was not 
the same as GBM-CM, confirming the aberrant pro-angiogenic microenvironment specific of GBM. Overall, our 
results obtained from co-culture systems indicated that GBM-CM, but not LGG-CM and MNG-CM, induced a 
resistant behaviour to anticancer drug TMZ in T89G cells, suggesting that the difference in tumor microenviron-
ment or tumor malignancy may affect tumor response to drugs46. In conclusion, our results allow us to develop 
a tumor-derived EC platform, biologically as close as possible to the in situ situation, as “disease in a dish”, to 
provide a further piece of the puzzle of the different grade-related angiogenic properties of human brain cancers. 
This tool has a high potential to test different anti-antiangiogenic drugs, in order to improve targeted approaches 
to GBM therapy.
Methods
Tumor samples processing and EC isolation. Tissue samples from patients who underwent surgical 
resection of GBM, LGG, MNG (n = 5 for each type) were at the Neurosurgery Unit of Fondazione IRCCS Ca’ 
Granda Ospedale Maggiore Policlinico (Milan, Italy) were included in the study (Table 1). The Institutional 
Review Board approved the protocol and all patients provided informed consent. All research was performed 
in accordance with relevant guidelines and regulations. Tumor specimens were washed in D-PBS (Euroclone, 
Milan, Italy) and suspended in DMEM/F12 (ThermoFisher, Waltham, Massachusetts) containing 1% penicillin/
streptomycin at 4 °C, for up to 24 h after surgery. For each sample, an aliquot of tissue was frozen dry at −80 °C 
for successive analysis, whereas another aliquot was processed by finely mincing with surgical scalpel in D-PBS 
and antibiotics. After shredding, samples were enzymatically digested with 0.625 Wu/ml Liberase Blendzyme 2 
(Roche, Mannheim, Germany) for 1 h at 37 °C. Cells were plated into 25 cm2-flask coated with bovine type I col-
lagen (BD Biosciences, Milan, Italy) and cultured in endothelial proliferation medium EndoPM at 37 °C, 5%CO2, 
5%O2, according to published protocol by Navone et al.47, (Supplementary Fig. 1). The media were changed 1-2 
times a week and passaged at a split ratio of 1:4 every 14 days ECs (n = 5 for each tumor subtype) were used for 
each assay.
T98G cell culture. T98G were purchased by the Istituto Zooprofilattico Sperimentale della Lombardia e dell’ 
Emilia Romagna (Brescia, Italy) and cultured in DMEM High Glucose additioned with 10% Fetal Bovine Serum 
(FBS), 1% sodium pyruvate (Sigma), 1% glutamine and 1% penicillin/streptomycin. Cells were maintained at 
37 °C, 5%CO2 and passaged at a split ratio of 1:2 every 5 days.
Immunohistochemistry. GBM, LGG and MNG specimens were fixed in 4% paraformaldehyde (PFA) and 
0.1 M D-PBS, embedded in paraffin and sectioned (10 µm) on a microtome. After inhibition of the endogenous 
peroxidases with 1% H2O2, sections were incubated in 1% BSA (Sigma Aldrich) with 0.2% Triton X-100 for 1 h, 
and then incubated overnight with primary antibodies anti-CD34 at 4 °C. The antibody staining was revealed 
using a biotinylated secondary antibody diluted with 0.1% BSA in D-PBS. For detection, the Novolink Polymer 
Detection System was used. Immunohistochemical data from tumour tissues were independently evaluated by 
two histopathologists.
Immunofluorescence analysis. ECs (1 × 104/well) were seeded into µ-Slide 8 Well, ibiTreat (Ibidi, 
Martinsried, Germany) collagen-coated. When cells reached the desired confluence and were fixed in par-
aformaldehyde 4% for 20 min at RT, washed twice with D-PBS and incubated with 0.1 M glycine to quench 
auto-fluorescence. Then, the coverslip was incubated with PBS + 0.25%Triton x100 to permeabilize cell mem-
branes and then blocked in PBS + 5%BSA for 30 min at RT. Incubation with primary antibodies (AB-I) diluted 
in blocking buffer was performed overnight at 4 °C. The following AB-I were used: anti-VWF (ThermoFisher, 
Tumor grade Age Ki67 IDH status MGMT methylation LOH 1p/19q
GBMs
Glioblastoma (WHO IV) 61 55% wt 58% wt
Glioblastoma (WHO IV) 58 30% wt 30% wt
Glioblastoma (WHO IV) 59 30% wt 34% LOH
Glioblastoma (WHO IV) 63 35% wt 44% wt
Glioblastoma (WHO IV) 62 35% wt 40% wt
LGGs
Diffuse Astrocytoma (WHO II) 56 1% wt 14% wt
Diffuse Astrocytoma (WHO II) 72 30% wt 4% wt
Diffuse Astrocytoma (WHO II) 62 13% wt 42% wt
Oligodendroglioma (WHO II) 48 1% mut 22% LOH
Oligodendroglioma (WHO II) 58 10% mut 10% LOH
MNGs
Meningioma (WHO I) 74 13% / / /
Meningioma (WHO I) 52 1% / / /
Meningioma (WHO I) 59 15% / / /
Meningioma (WHO I) 63 7% / / /
Meningioma (WHO I) 88 5% / / /
Table 1. Main characteristics of brain tumor samples included in the study.
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Waltham, Massachusetts), anti-VEGFR-1 (ReliaTech GmbH, Wolfenbüttel, Germany), and anti-VE-Cadherin 
(Santa Cruz Biotechnology, Heidelberg, Germany) as specific markers for endothelial cells. To confirm EC high 
purity immunostaining with GFAP (1:100, BD), CD68 (1:100) and smooth muscle actin (SMA, 1:50) (both from 
SantaCruz Biotechnology) were performed. The following day, AB-I was removed and fluorescent secondary 
antibody (AB-II) labelling was then added for 45 min at RT, protected from light. After incubation with AB-II 
and two washes with D-PBS, DAPI (1 μg/ml, ThermoFisher) staining was performed for 3 min at RT and cov-
erlips were mounted with ProLong Gold Antifade Mountant (ThermoFisher). Immunolabeling was acquired 
using an inverted DMI4 microscope equipped with DFC350xCCDcamera and LAS-X software (all from Leica 
Microsystems, Wetzlar, Germany).
Flowcytometric analysis (FACS). ECs (1 × 105/tube) were resuspended in 200 μl of D-PBS and stained 
with FITC-conjugated anti-human CD105 and PE- conjugated anti-human CD133, anti-human CD56, 
anti-human CD90 (all purchased by BD Biosciences), for 20 min at RT in the dark. In order to exclude dead cells 
from the analysis, 7-aminoactinomycin D (7-AAD, BD) was added to each tube. Flow cytometric analysis were 
performed using FACScalibur flow cytometer Cell Quest software (FACS, BD Bioscience, version 8.0).
Estimation of proliferation rate. ECs (5 × 104) were seeded into 25 cm2 collagen-coated flask, cultured in 
EndoPM at 37 °C, 5%CO2, 5%O2 and passaged at a split ratio of 1:2, as they were in confluence. At each passage 
time point, ECs detached by TrypLE Select were stained with Trypan Blue (ThermoFisher) and counted in a 
Fuchs Rosenthal counting chamber, to evaluate growth rate.
Vascular permeability assay. Transwell insert (0.4 μm pore size, Corning, Corning, USA) were coated 
with bovine type I collagen for 45 min at 37 °C. After complete drying, GBM-ECs, LGG-ECs and MNG-ECs 
(2 × 104) were seeded on the insert and cultured with 150 μl and 650 μl of EndoPM in the upper chamber and 
in the lower chamber, respectively. ECs were cultured for 3 days at 37 °C, 5%CO2, 5%O2, until they reached the 
appropriate confluence, and then FITC-70 kDa dextran (Sigma Aldrich) was added to the insert (4 μl, 25 mg/ml 
initial concentration). Every 30 min, 10 μl of EndoPM were collected from the lower chamber, for a total of 7 sam-
ples (30 min, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 6 h). After the latest time point (6 h), each sample was diluted to 200 μl with 
1 × D-PBS and 100 μl of each diluted sample were transferred in duplicate into 96-well black plates. Fluorescent 
content of the samples was measured at 492/520 nm absorption/emission wavelengths for FITC-dextran, with 
Tecan Infinite 200 PRO.
Drug treatment. In order to evaluate the effect of drug inhibition on GBM-ECs (n = 5), cell culture treat-
ments with Bevacizumab (BEV, Avastin®, Roche) at concentrations of 100 µg/ml and 200 µg/ml, Temozolomide 
(TMZ, Schering-Plough, Milano) at 100 µM and 200 µM, and Sunitinib (SUN, Sigma Aldrich) at 5 µM and 10 µM, 
were performed for 24 h and 48 h.
In order to evaluate the influence of ECs on drug sensitivity/resistance of GBM tumor cells, conditioned media 
(CM) by GBM-ECs, LGG-ECs and MNG-ECs were placed on T98G cell cultures for 48 h. Briefly, GBM-ECs, 
LGG-ECs and MNG-ECs (1 × 105/well) were cultured into 6-well cell culture plates collagen-coated in EndoPM 
at 37 °C, 5%CO2, 5%O2. After 3 days, media were collected, centrifuged 300 gx5 min to eliminate cell debris, and 
stored at −20 °C.
MTT assay. 3-(4,5-Dimethylthiazol-2-yl)−2,5-Diphenyltetrazolium Bromide (MTT) assay was used to 
assess cell viability as a function of redox potential. GBM-ECs and T98G (5 × 103/well) were seeded and cul-
tured in 96-well plate for 24 h. Then, culture media were replaced with fresh media containing the specific treat-
ments. Tests were performed in triplicate following 24 h and 48 h of treatment. At each time point, culture media 
were replaced with 100 μl of fresh media + 10 µl of MTT 5 mg/ml in D-PBS. After 4 h of incubation, media were 
removed and cells were lysed with 100 µl of 2-propanol/formic acid (95:5, by vol) for 10 min. Then, absorbance 
was read at 570 nm in microplate reader.
Tube Formation Assay. µ-Plate Angiogenesis 96 Well (Ibidi) were coated with 12.5 mg/mL Matrigel (BD 
Bioscience), 10 μL/well, at 4 °C. After gentle agitation to ensure complete coating, plates were incubated for 
30 minutes at 37 °C to allow solidification of Matrigel. ECs (1 × 104/well) from GBM, LGG and MNG were seeded 
in triplicate in EndoPM and incubated at 37 °C, 5%CO2, 5%O2. Cord formation was monitored with an inverted 
Eclipse Ti-E microscope (Nikon Instruments, Florence, Italy), equipped with a high resolution cSMOS camera 
(Andor Zyla, Andor Technology, Belfast, UK) and NIS_Elements 4.51 software, using differential interference 
contrast (DIC). After 24 h of incubation, five random images were acquired and analysed with “Angiogenesis 
Analyzer” plugin in Image48. Tube formation assay was performed following the same protocol on GBM-ECs 
in presence or absence of BEV(100 μg/ml and 200 μg/ml) and TMZ (100 μM and 200 μM) and SUN (5 µM and 
10 µM) at 24 h and 48 h after treatments.
Quantitative real-time PCR analysis (qRT-PCR) on tissue homogenates. Tissue specimen of 
GBMs, LGGs and MNGs previously stored at −80 °C, were thawed and 1 ml of TRI-Reagent Solution (Thermo 
Fisher Scientific) was added. Homogenization of tumor samples was performed using TissueRuptor (Qiagen). 
GBM-ECs and T98G cells (1 × 105/well) were seeded into 6-well cell culture plates and cultured with the appro-
priate medium until 80% confluence was reached. Then, media were replaced with fresh media containing basal 
medium, as control, or additioned with treatments listed above. Treatments lasted 24 h and 48 h for ECs, and 
48 h for T98G cells. Total RNA was extracted following TRI-Reagent protocol and quantified with NanoDrop 
1000 Spectrophotometer (Thermo Fisher Scientific). Reverse transcriptase reaction was executed using qScript 
cDNA SuperMix (QuantaBio), loading 1 μg of RNA (A260/A280 > 1.8), according to manufacturer’s instructions. 
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qRT-PCR was performed using StepOnePlus™ (Thermo Fisher Scientific) using 1 μg of cDNA, forward and 
reverse primers (250 nM each one) and PowerUp SYBR Green Master Mix (ThermoFisher), in a final volume 
of 20 μl. Primers used for qRT-PCR analysis are listed in Supplementary Table 2. Data were normalized to 18S 
expression, used as endogenous control. Relative gene expression was determined using the 2−ΔΔCt method. 
In qRT-PCR comparing gene expression of different tumor grade, expression was compared to cDNA of healthy 
brain tissue (HB), purchased by Invitrogen (ThermoFisher), whereas for GBM-ECs and T98G treated, expression 
was compared to untreated control (CTRL).
Statistical analysis. All analyses were done with SPSS software (release 25.0, IBM Corp., Armonk, New 
York). Parameters in the three groups (GBM, LGG, and MNG) were compared and analysed by a one-way anal-
ysis of variance (ANOVA). When significant differences were detected, Bonferroni post hoc comparisons were 
made. The Kruskal-Wallis test was used to compare and analyze non-parametric data following treatments in 
GBM-ECs and T98G cells. Differences were considered statistically significant for p < 0.05.
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